Biofrontera AG
XETRA:B8F
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biofrontera AG
XETRA:B8F
|
DE |
|
Boliden AB
STO:BOL
|
SE |
|
Bank Polska Kasa Opieki SA
LSE:0DP0
|
PL |
|
Marvell Technology Inc
MIL:19MW
|
US |
|
DURECT Corp
NASDAQ:DRRX
|
US |
|
D
|
DRDGOLD Ltd
JSE:DRD
|
ZA |
|
Monrif SpA
MIL:MON
|
IT |
|
Excelerate Energy Inc
NYSE:EE
|
US |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is B8F's stock price target?
Not Available
B8F doesn't have any price targets made by Wall Street professionals.
What is Biofrontera AG's Revenue forecast?
Projected CAGR
32%
For the last 1 year the
compound annual growth rate for
Biofrontera AG's revenue is
25%.
The projected
CAGR
for the next 2 years is
32%.